The estimated Net Worth of Marcea Bland Lloyd is at least 29 千$ dollars as of 14 July 2020. Marcea Lloyd owns over 10,000 units of Poseida Therapeutics stock worth over 29,000$ and over the last 4 years Marcea sold PSTX stock worth over 0$.
Marcea has made over 1 trades of the Poseida Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Marcea bought 10,000 units of PSTX stock worth 160,000$ on 14 July 2020.
The largest trade Marcea's ever made was buying 10,000 units of Poseida Therapeutics stock on 14 July 2020 worth over 160,000$. On average, Marcea trades about 1,429 units every 0 days since 2020. As of 14 July 2020 Marcea still owns at least 10,000 units of Poseida Therapeutics stock.
You can see the complete history of Marcea Lloyd stock trades at the bottom of the page.
Marcea's mailing address filed with the SEC is C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTER DRIVE SUITE 200, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Poseida Therapeutics have traded over 7,666,974$ worth of Poseida Therapeutics stock and bought 3,065,405 units worth 15,916,632$ . The most active insiders traders include David Hirsch、Life Sciences Holdings Ltd ...、Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of 303,665$. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth 500,000$.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics executives and other stock owners filed with the SEC include: